Application of DNA damage response gene related SNPs in treatment and prognosis of acute myeloid leukemia
By detecting DNA damage response gene-related SNPs, especially LIG3 rs3744356, the risk and prognosis of acute myeloid leukemia were assessed, which solved the problem of unclear role of SNPs in the DDR pathway in AML and enabled precise assessment and prediction of AML treatment.
CN122235310APending Publication Date: 2026-06-19SHANDONG UNIV QILU HOSPITAL
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SHANDONG UNIV QILU HOSPITAL
- Filing Date
- 2026-05-18
- Publication Date
- 2026-06-19
Smart Images
Figure CN122235310A_ABST
Abstract
This invention belongs to the field of biomedical technology, specifically relating to the application of DNA damage response gene-related SNPs in the treatment and prognosis of acute myeloid leukemia (AML). This invention is the first to discover that single nucleotide polymorphisms (SNPs) in the DNA damage response pathway (focusing on three major functional modules: damage sensing, signal transduction, and DNA repair) are closely related to the clinical characteristics, treatment response, and survival prognosis of AML. This lays the foundation for constructing a multi-gene risk model based on the DNA damage response pathway and provides theoretical support for integrating germline SNP maps into precision medicine strategies for AML.
Need to check novelty before this filing date? Find Prior Art